The MIT Health and Life Sciences Collaborative (MIT HEALS) has announced the establishment of the Fairbairn Menstruation Science Fund, supporting a bold, high-impact initiative designed to revolutionize women's health research.
Established through a gift from Emily and Malcolm Fairbairn, the fund will advance groundbreaking research on the function of the human uterus and its impact on sex-based differences in human immunology that contribute to gynecological disorders such as endometriosis, as well as other chronic systemic inflammatory diseases that disproportionately affect women, such as Lyme disease and lupus. The Fairbairns, based in the San Francisco Bay Area, have committed $10 million, with a call to action for an additional $10 million in matching funds.
"I'm deeply grateful to Emily and Malcolm Fairbairn for their visionary support of menstruation science at MIT. For too long, this area of research has lacked broad scientific investment and visibility, despite its profound impact on the health and lives of over half the population," says Anantha P. Chandrakasan, MIT provost who was chief innovation and strategy officer and dean of engineering at the time of the gift, and Vannevar Bush Professor of Electrical Engineering and Computer Science.
Chandrakasan adds: "Thanks to groundbreaking work from researchers like Professor Linda Griffith and her team at the MIT Center for Gynepathology Research (CGR), we have an opportunity to advance our understanding and address critical challenges in menstruation science."
Griffith, professor of biological and mechanical engineering and director of CGR, says the Fairbairn Fund will permit the illumination of "the enormous sex-based differences in human immunity" and advance next-generation drug-discovery technologies.
One main thrust of the new initiative will further the development of "organs on chips," living models of patients. Using living cells or tissues, such devices allow researchers to replicate and experiment with interactions that can occur in the body. Griffith and an interdisciplinary team of researchers have engineered a powerful microfluidic platform that supports chips that foster growth of tissues complete with blood vessels and circulating immune cells. The technology was developed for building endometriosis lesions from individual patients with known clinical characteristics. The chip allows the researchers to do preclinical testing of drugs on the human patient-derived endometriosis model rather than on laboratory animals, which often do not menstruate naturally and whose immune systems function differently than that of humans.
The Fairbairn Fund will build the infrastructure for a "living patient avatar" facility to develop such physiomimetic models for all kinds of health conditions.
"We acknowledge that there are some big-picture phenomenological questions that one can study in animals, but human immunology is so very different," Griffith says. "Pharma and biotech realize that we need living models of patients and the computational models of carefully curated patient data if we are to move into greater success in clinical trials."
The computational models of patient data that Griffith refers to are a key element in choosing how to design the patient avatars and determine which therapeutics to test on them. For instance, by using systems biology analysis of inflammation in patient abdominal fluid, Griffith and her collaborators identified an intracellular enzyme called jun kinase (JNK). They are now working with a biotech company to test specific inhibitors of JNK in their model. Griffith has also collaborated with Michal "Mikki" Tal, a principal scientist in MIT's Department of Biological Engineering, on investigating a possible link between prior infection, such as by the Lyme-causing bacterium Borrelia, and a number of chronic inflammatory diseases in women. Automating assays of patient samples for higher throughput could systematically speed the generation of hypotheses guiding the development of patient model experimentation.
"This fund is catalytic," Griffith says. "Industry and government, along with other foundations, will invest if the foundational infrastructure exists. They want to employ the technologies, but it is hard to get them developed to the point they are proven to be useful. This gets us through that difficult part of the journey."
The fund will also support public engagement efforts to reduce stigma around menstruation and neglect of such conditions as abnormal uterine bleeding and debilitating anemia, endometriosis, and polycystic ovary syndrome - and in general bring greater attention to women's health research. Endometriosis, for instance, in which tissue that resembles the uterine lining starts growing outside the uterus and causes painful inflammation, affects one in 10 women. It often goes undiagnosed for years, and can require repeated surgeries to remove its lesions. Meanwhile, little is known about what causes it, how to prevent it, or what could effectively stop it.
Women's health research could further advance in many areas of medicine beyond conditions that disproportionately affect females. Griffith points out that the uterus, which sheds and regenerates its lining every month, demonstrates "scarless healing" that could warrant investigation. Also, deepened study of the uterus could shed light on immune tolerance for transplants, given that in a successful pregnancy an implanted fetus is not rejected, despite containing foreign material from the biological father.
For Emily Fairbairn, the fund is a critical step toward major advances in an often-overlooked area of medicine.
"My mission is to support intellectually honest, open-minded scientists who embrace risk, treat failure as feedback, and remain committed to discovery over dogma. This fund is a direct extension of that philosophy. It's designed to fuel research into the biological realities of diseases that remain poorly understood, frequently dismissed, or disproportionately misdiagnosed in women," Fairbairn says. "I've chosen to make this gift to MIT because Linda Griffith exemplifies the rare combination of scientific integrity and bold innovation - qualities essential for tackling the most neglected challenges in medicine."
Fairbairn also refers to Griffith collaborator Michal Tal as being "deeply inspiring."
"Her work embodies what's possible when scientific excellence meets institutional courage. It is this spirit - bold, rigorous, and fearless - that inspired this gift and fuels our hope for the future of women's health," she says.
Fairbairn, who has suffered from both Lyme disease and endometriosis that required multiple surgeries, originally directed her philanthropy, including previous gifts to MIT, toward the study of Lyme disease and associated infections.
"My own experience with both Lyme and endometriosis deepened my conviction that science must better account for how female physiology, genetics, and psychology differ from men's," she says. "MIT stands out for treating women's health not as a niche, but as a frontier. The Institute's willingness to bridge immunology, neurobiology, bioengineering, and data science - alongside its development of cutting-edge platforms like human chips - offers a rare and necessary seriousness of purpose."
For her part, Griffith refers to Fairbairn as "a citizen scientist who inspires us daily."
"Her tireless advocacy for patients, especially women, who are dismissed and gas-lit, is priceless," Griffith adds. "Emily has made me a better scientist, in service of humanity."
